Background Though mammographic density (MD) has been proposed as an intermediate marker of breast cancer risk, few studies have examined whether the associations between breast cancer risk factors and risk are mediated by MD, particularly by tumor characteristics. Methods Our study population included 3392 cases (1105 premenopausal) and 8882 (3192 premenopausal) controls from four case-control studies. For established risk factors, we estimated the percent of the total risk factor association with breast cancer that was mediated by percent MD (secondarily, by dense area and non-dense area) for invasive breast cancer as well as for subtypes defined by the estrogen receptor (ER+/ER−), progesterone receptor (PR+/PR−), and HER2 (HER2+/HER2−). Analyses were conducted separately in pre-and postmenopausal women. Results Positive associations between prior breast biopsy and risk of invasive breast cancer as well as all subtypes were partially mediated by percent MD in pre-and postmenopausal women (percent mediated = 11-27%, p ≤ 0.02). In postmenopausal women, nulliparity and hormone therapy use were positively associated with invasive, ER+ , PR+ , and HER2− breast cancer; percent MD partially mediated these associations (percent mediated ≥ 31%, p ≤ 0.02). Further, among postmenopausal women, percent MD partially mediated the positive association between later age at first birth and invasive as well as ER+ breast cancer (percent mediated = 16%, p ≤ 0.05). Conclusion Percent MD partially mediated the associations between breast biopsy, nulliparity, age at first birth, and hormone therapy with risk of breast cancer, particularly among postmenopausal women, suggesting that these risk factors at least partially influence breast cancer risk through changes in breast tissue composition.
Introduction
High percent mammographic density (MD), or the proportion of dense breast tissue on a mammogram, is one of the strongest risk factors for breast cancer [1] . Further, MD varies by anthropometric, reproductive, and lifestyle breast cancer risk factors, suggesting that MD may be a potential surrogate marker for breast cancer risk [2] . However, the extent to which MD acts as a mediator for established breast cancer risk factors is not well understood as few studies have examined whether MD mediates the associations between these factors and breast cancer risk [3] [4] [5] [6] . In a recent analysis in the Nurses' Health Study (NHS) and NHSII, we observed that MD mediated the associations for some risk factors, including benign breast disease, but not others, such as family history of breast cancer [5] . One of the primary limitations of this prior analysis was limited power to assess mediation by breast cancer tumor characteristics. As the associations between some breast cancer risk factors, including MD, vary by tumor characteristics, the extent to which MD acts as a mediator of the associations with breast cancer 1 3 risk factors may also vary by tumor characteristics. Therefore, the purpose of this analysis was to confirm our prior observations in the NHS/NHSII for all invasive breast cancer with the following exposures: current body mass index (BMI), height, age at menarche, parity, age at first birth, alcohol use, family history of breast cancer, and hormone therapy (HT) use. Further, as the associations between breast cancer risk factors, including MD, may vary by breast tumor characteristics, we sought to quantify the extent to which the associations between these risk factors as well as prior breast biopsy and risk of breast cancer subtypes defined by tumor markers [specifically defined by the estrogen receptor (ER+, ER−), progesterone receptor (PR+, PR−), and human epidermal growth factor receptor 2 (HER2+, HER2−)] were mediated by percent MD in a larger study [7] . Lastly, in secondary analyses, we extended our prior work and investigated the extent to which both absolute dense area as well as absolute non-dense area on a mammogram mediated these associations.
Materials and methods

Study populations
We included data from four nested case-control studies of breast cancer: the Mayo Mammography Health Study (MMHS), the Nurses' Health Study (NHS), the Nurses' Health Study II (NHSII), and the San Francisco Bay Area Breast Cancer SPORE and San Francisco Mammography Registry (SFMR). Details of these studies and the study populations have been previously described [7, 8] . Incident invasive cases of breast cancer were identified by self-report, linkage to clinic and/or statewide tumor registries, or death certificates. Medical records were reviewed to further confirm disease status. Controls were selected from the underlying cohorts and were matched to cases on age, menopausal status, and year of examination (MMHS, SFMR) or blood draw (NHS, NHSII) as previously described [7, 8] . All mammograms were taken prior to case diagnosis; further cases who were diagnosed within 6 months of the study mammogram as well as their matched controls were excluded to ensure we captured only incident cases. The following risk factors were selected for analysis: current BMI, height, age at menarche, parity, age at first birth, alcohol use, family history of breast cancer, previous breast biopsy, age at menopause (postmenopausal only), and HT use (postmenopausal only). Information on these selected risk factors were obtained from self-administered questionnaires (NHS, NHSII), or both medical record review and self-administered questionnaires (MMHS,) before (NHS, NHSII) or at the time of (MMHS, SFMR) mammography. All risk factors are at time of mammography. We excluded 24 women (2 cases, 22 controls) without information on BMI. In total, these analyses included 3392 breast cancer cases and 8882 controls.
For all breast cancer cases, we obtained information on ER, PR, and HER2 status of breast tumors from medical records (MMHS), state and clinic cancer registries (MMHS,), statewide surveillance epidemiology and end results programs (SFMR), and pathology reports (NHS, NHSII). For a subset of cases in NHS and NHSII without receptor expression information on pathology reports, we conducted immunohistochemical staining of paraffin sections from core biopsies or tumor microarrays per standard protocols as described previously [7, 9] . This study was approved by the Institutional Review Boards at Mayo Clinic (Rochester, MN), Brigham and Women's Hospital (Boston, MA), and the University of California, San Francisco (UCSF, San Francisco, CA). Informed consent was obtained (MMHS, SFMR) or implied by return of questionnaires (NHS, NHSII).
Mammographic density
Mammographic density measurements in the four studies have been described previously [7, 8] . Briefly, we measured dense area as well as total breast area from craniocaudal pre-diagnosis film screening mammograms using computerassisted threshold techniques (Cumulus and UCSF custom software) [10, 11] . Percent MD was calculated as dense area divided by total breast area, whereas non-dense area was calculated as total area minus dense area. In the NHS and NHSII, we averaged the MD measurements of both breasts. For the remaining studies, MD was measured in the contralateral breast for cases and for the same side in the matched controls.
Statistical analysis
Means and frequencies of anthropometric, reproductive, and lifestyle risk factors were calculated by case status as well as across quartiles of percent MD among the controls stratified by menopausal status. For all analyses, MD measures were square-root transformed to improve normality. We used linear regression to estimate differences in the square-root transformed MD measures by the selected risk factors among the controls. Using the SAS macro developed by Spiegelman and colleagues (https ://www.hsph.harva rd.edu/donna -spieg elman /softw are/media te), based on the mediation analysis method outlined by Nevo et al., we quantified the extent to which the associations between each of the exposures and breast cancer risk were mediated by MD [12] . Using data augmentation and logistic regression, we estimated the odds ratio (OR) and 95% confidence interval (CI) for (a) the association between the given risk factor and breast cancer risk not adjusted for MD [i.e., the total association between the risk factor and breast cancer risk] and (b) the association between the given risk factor and breast cancer risk adjusted for continuous square-root transformed MD [i.e., the association between the risk factor and breast cancer risk not through MD]. Using these estimates, we next calculated the percent of the total association (on the log odds scale) between the exposure and breast cancer risk that was mediated by MD. As percent MD is a stronger predictor of breast cancer than either absolute dense or non-dense area, our primary analysis examined percent MD as a potential mediator [13] . However, as both dense area and non-dense area have been independently associated with breast cancer risk (in opposite directions) in our prior research, we also examined mediation of the associations by these measures in secondary analyses with mutual adjustment for both measures [8, 13] .
Exposure variables were modeled continuously except for the following binary variables: nulliparity (nulliparous vs. parous), age at first birth (≥ 30 vs. < 30 years of age), first-degree family history of breast cancer (yes vs. no), prior breast biopsy (yes vs. no), and current HT use (any HT, estrogen-only HT, estrogen plus progestin HT) among postmenopausal women (vs. never/former use). Models were adjusted for potential confounders of the association between the exposures and breast cancer risk, potential confounders of the association between the exposures and MD, and potential confounders of the association between MD and breast cancer risk. These covariates were age (continuous), BMI (continuous), study (indicators for each study), parity/age at first birth (nulliparous, < 30, ≥ 30), prior breast biopsy (yes, no), family history of breast cancer (yes, no), and any HT use (current, never/former). A priori, all analyses were conducted separately in pre-and postmenopausal women with menopausal status defined at the time of the mammogram. In a sensitivity analysis, we excluded the NHS and NHSII from the analyses for all invasive breast cancer to confirm these results were consistent in the MMHS and SFMR. Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC), and results were considered statistically significant if p < 0.05.
Results
Among both pre-and postmenopausal women as well as across the four studies, cases had higher mean percent MD, higher mean dense area, and lower mean non-dense area compared to controls as expected (Table 1 and Supplementary Table 1 ). Cases were also more likely to be nulliparous, have a later age at first birth, to have a family history of breast cancer, and to have had a prior breast biopsy. BMI and number of children among parous women were inversely associated with percent MD while age at menarche, nulliparity, prior breast biopsy, and current postmenopausal HT use were positively associated with percent MD, with a stronger association for estrogen plus progestin compared to estrogen-only HT use (Supplementary Tables 2,  3 ). The median time between mammogram and breast cancer diagnosis was 4.3 (IQR: 2.7, 6.3) years.
Premenopausal women
All invasive breast cancer
Among women who were premenopausal at time of mammogram, greater age at first birth (OR ≥ 30 vs. < 30 years of age = 1.32, 95% CI 1.09, 1.60), family history of breast cancer (OR yes vs. no = 1.59, 95% CI 1.30, 1.94), and prior breast biopsy (OR yes vs. no = 1.76, 95% CI 1.48, 2.10) were positively associated with invasive breast cancer risk in the multivariable model ( Table 2 ). While percent MD did not mediate the associations between age at first birth or family history of breast cancer and breast cancer risk (percent mediated = 5%, p ≥ 0.18), the association with prior breast biopsy was significantly mediated by percent MD (percent mediated = 17%, p < 0.01). Both dense area and non-dense area significantly mediated the association with prior breast biopsy in premenopausal women, though the percent mediated was greater for dense area (percent mediated = 10%, p < 0.01) compared to non-dense area (percent mediated = 5%, p < 0.01) (Supplemental Tables 4, 5 ). Age at menarche was inversely associated with overall breast cancer risk (OR 0.86, 95% CI 0.75, 1.00), but there was no evidence of mediation by percent MD. None of the other factors evaluated, including current BMI, height, parity (nulliparous vs parous), number of births among parous women, or alcohol use were significantly associated with invasive breast cancer risk in these analyses among premenopausal women; therefore percent MD did not significantly mediate any associations with these factors (Table 2) . Results were similar when we excluded the NHS and NHSII from analyses (data not shown).
Breast cancer subtypes
When we examined the associations by breast cancer subtype defined by ER, PR, or HER2 status in premenopausal women, previous breast biopsy remained a strong, significant risk factor for all subtypes (ORs 1.68-2.07); these associations were significantly mediated by percent MD (percent mediated = 11-18%, p ≤ 0.02) ( Table 2 ). In addition, dense area significantly mediated the associations with prior biopsy for all breast cancer subtypes (percent mediated = 6-12%, p ≤ 0.03), while the proportions of the associations mediated by non-dense area were lower (percent mediated = 4-6%, p ≤ 0.09) (Supplemental Tables 4, 5 ). 
Postmenopausal women
All invasive breast cancer
Among women who were postmenopausal at the time of mammogram, BMI (OR per 5 kg/m 2 increase = 1.14, 95% CI 1.09, 1.19), nulliparity (OR nulliparous vs. parous = 1.23, 95% CI 1.07, 1.41), later age at first birth (OR ≥ 30 vs. < 30 years of age = 1.26, 95% CI 1.08, 1.47), family history of breast cancer (OR yes vs. no = 1.58, 95% CI 1.39, 1.80), later age at menopause (OR per category increase = 1.07, 95% CI 1.02, 1.13), previous breast biopsy (OR yes vs. no = 1.50, 95% CI 1.34, 1.69), current use of any HT (OR current vs never/past = 1.39, 95% CI 1.24, 1.55), current estrogen-only HT use (OR current vs never/past = 1.16, 95% CI 1.00, 1.34), and current estrogen plus progestin (OR current vs. never/past = 1.66, 95% CI 1.45, 1.90) were significantly positively associated with all invasive breast cancer risk (Table 3) . Further, height was suggestively positively associated with risk of all invasive breast cancer (OR per 3-inch increase = 1.06, 95% CI 0.99, 1.12). Percent MD did not mediate the associations with BMI, height, family history of breast cancer, or later age at menopause. However, percent MD did significantly mediate the associations between the following risk factors and all invasive breast cancer among postmenopausal women: nulliparity (percent mediated = 43%, p < 0.01), age at first birth (percent mediated = 16%, p = 0.05), prior breast biopsy (percent mediated = 24%, p < 0.01), current HT use (percent mediated = 37%, p < 0.01), and current estrogen plus progestin HT use (percent mediated = 26%, p < 0.01). Further, while not statistically significant, percent MD did appear to mediate the associate with current estrogen-only HT use (percent mediated = 69%, p = 0.06). In general, both dense area and non-dense area also significantly mediated these associations, though the percent mediated was greater for dense area (Supplemental Table 6 ) compared to non-dense area (Supplemental Table 7 ). Age at menarche, number of births among parous women, and alcohol use were not significantly associated with risk of all invasive breast cancer or breast cancer subtypes in this sample of postmenopausal women; therefore percent MD did not significantly mediate any associations with these factors. Results were generally similar when we excluded the NHS and NHSII (data not shown).
Breast cancer subtypes
Among postmenopausal women, family history of breast cancer (ORs 1.52-2.01) as well as prior breast biopsy (ORs 1.47-1.68) were significantly positively associated Number of individuals' missing data on the following variables: height (n = 1144), alcohol (n = 7144), parity (n = 6337), age at menarche (n = 5484), age at first birth (n = 2662), age at menopause (n = 1463), current HT (n = 1054), nulliparous (n = 266), family history of breast cancer (n = 144), previous breast biopsy (n = 245), type of hormone therapy (N = 7)
BMI body mass index, E estrogen, E + P estrogen plus progestin a Among parous with all breast cancer subtypes defined by ER, PR, or HER2 (Table 3) . Similar to the analysis in premenopausal women, percent MD significantly mediated the associations with prior breast biopsy (percent mediated = 18-27%, p < 0.01), but did not mediate the associations with family history of breast cancer (percent mediated ≤ 2%, p ≥ 0.44). Further, dense area significantly mediated the associations with prior biopsy for all subtypes (percent mediated = 9-19%, p ≤ 0.01), while non-dense area significantly mediated the associations with prior biopsy for ER+ (percent mediated = 5%, p = 0.01) and PR+ (percent mediated = 5%, p = 0.01) tumors. For BMI, height, nulliparity, age at first birth, age at menopause, and current HT use, results for ER+, PR+, and HER2− breast cancer were generally similar to the results for all invasive breast cancer. Older age at first birth was also positively associated with HER2+ breast cancer (OR 1.61, 95% CI 1.13, 2.30,), though the association was not mediated by percent MD (percent mediated = 6%, p = 0.09).
Discussion
Among postmenopausal women, percent MD partially mediated the associations between prior breast biopsy, age at first birth, nulliparity, and current hormone therapy with risk of breast cancer and subtypes. Among premenopausal women, however, percent MD partially mediated the association with invasive breast cancer for prior breast biopsy, Adjusted for age (continuous), current BMI (continuous), study (MMHS, NHS, NHSII, SFMR), parity/age at first birth (nulliparous, parous age at first birth < 30, parous age at first birth ≥ 30), previous breast biopsy (no, yes, unknown), and family history of breast cancer (no, yes, unknown)
Not mediated = percent mediated calculated to be < 0% or > 100%
BMI body mass index a Not adjusted for parity/age at first birth b Among parous c p value for percent of the total association mediated by mammographic density d Square-root transformed but did not mediate the observed association with age at first birth. Though family history was strongly associated with invasive breast cancer as well as most subtypes, percent MD did not mediate the associations in pre-or postmenopausal women. Our observations for all invasive breast cancer were consistent with a prior study in the NHS/NHSII, even after exclusion of those cohorts in this analysis [5] . In general, our results for ER+, PR+, and HER2− tumors were similar to those observed for all invasive breast cancer. While percent MD was the strongest mediator of these associations, dense area and non-dense area did mediate some of the associations. In general, the percent mediated was greater for dense area compared to non-dense area. Though we observed significant mediation by percent MD of the association between prior breast biopsy and breast cancer risk in pre-and postmenopausal women, this result should be cautiously interpreted. While prior breast biopsy was assessed prior to MD measurements, it is likely that women also had high percent MD at the time of their biopsy. As women with denser breasts are more likely to undergo breast biopsy, breast biopsies may be a downstream consequence of high percent MD [14] . Therefore, it is difficult to determine the temporality between these two breast cancer risk factors.
Percent MD appeared to mediate the associations with current postmenopausal HT use for all invasive, ER+, PR+, and HER2− breast cancer, with mediation proportions ranging from 31 to 37%. This is consistent with observations that percent MD increases with use of postmenopausal HT and decreases with the administration of tamoxifen, a selective estrogen receptor modulator, suggesting that the breast is susceptible to hormonally related exogenous agents, even among postmenopausal women [15] [16] [17] . Further, this is supported by recent work in the Women's Health Initiative which observed that the association between estrogen plus progestin HT use (compared to placebo) and breast cancer risk was entirely mediated through the change in percent MD from baseline to 1 year post treatment arm assignment [6] . While we observed a lower percent mediation for estrogen plus progestin use relative to this prior study, current users in our study population likely used different formulations for different lengths of time increasing heterogeneity in our exposure. Further, we assessed percent MD measured at one point in time rather than change in percent MD over time. In contrast to our observations for current HT use, we did not observe any evidence that percent MD is a mediator of the association between family history of breast cancer and risk of any breast cancer subtype. While evidence suggests that both MD and breast cancer risk are heritable, one explanation for a lack of mediation by percent MD of the association between family history and breast cancer risk may be that heritability of MD may act through different mechanisms than heritability of breast cancer risk [18] [19] [20] .
For example, studies have demonstrated that women with germline BRCA1/2 mutations do not have higher percent MD than women without these mutations [21] . However, GWAS studies suggest a shared genetic basis between MD and breast cancer as several breast cancer susceptibility loci have also been associated with MD [22] [23] [24] [25] [26] . This lack of consistency may be due to the fact that family history of breast cancer is a heterogeneous mix of genetic and nongenetic determinants; germline genetic information may be more appropriate for examining mediation due to heritability of breast cancer. For some of the breast cancer risk factors studied, differences were noted in the proportion of associations mediated by percent MD by menopausal status and tumor subtype. For example, while age at first birth ≥ 30 years of age was associated with an approximately 30% higher risk of all invasive breast cancer in both pre-and postmenopausal women, percent MD only significantly mediated the association in postmenopausal women. Further, mediation by percent MD among postmenopausal women was significant only for all invasive and ER+ tumors; age at first birth among postmenopausal women was not associated with ER-disease. For other risk factors, associations with breast cancer risk were observed in postmenopausal women, but not premenopausal women. For example, among postmenopausal women, those who were nulliparous had a 23-27% higher risk of all invasive, ER+, PR+, and HER2− tumors, whereas the associations were weaker and non-significant in premenopausal women. This disparity may be partially explained by the transient increase in breast cancer risk post-pregnancy, which is stronger and persists for a greater number of years in women with later ages at births [27] . In fact, premenopausal women in this study were approximately twice as likely to have an age at first birth of 30 years or older compared to postmenopausal women.
Although our study included over 3000 breast cancer cases and almost 9000 matched controls, we did have limited power for rarer subtype and exposure combinations within strata of menopausal status (e.g., family history of breast cancer and ER− breast cancer in premenopausal women). We also did not have sufficient power to assess mediation for intrinsic molecular subtypes of breast cancer [28] . Further some of the selected risk factors were not significantly associated with breast cancer risk within strata of menopausal status in this sample, limiting our ability to assess mediation by percent MD for these risk factors (e.g., height in premenopausal women). In particular, we had a smaller number of premenopausal cases, restricting our ability to assess mediation by percent MD in younger women. Unlike other approaches [29] , our method to assess mediation did not model interaction between the selected risk factors and MD on breast cancer risk; however, in our prior NHS/NHSII analysis, we observed little interaction between the selected exposures and MD [5] . Though MD measurements are highly reproducible, there may be some non-differential misclassification of MD which would likely bias our estimates of the percent mediated towards the null [30] . Further, data on some risk factors across the studies were collected through self-report; however, as data were collected prior to breast cancer diagnosis for most studies, any misclassification should be non-differential. We were unable to examine former and never HT users separately due to limitations in the data for some of the participating studies. While we were able to adjust for a large number of potential confounders, including strong predictors of MD such as BMI, we did not have information on early life body size (a risk factor for both MD and breast cancer) for two of the studies. Therefore, there may be some residual confounding; however, we would expect the degree of confounding to be modest. As ER, PR, and HER2 expression are correlated, analyses are not fully independent of each other. Lastly, we did not collect data on risk factors specific to rarer subtypes of breast cancer, such as ER−-related risk factors including early life body size, carotenoid intake, and breastfeeding. Strengths of this study include the large sample size, allowing for assessment of mediation by subtype of breast cancer, as well as detailed collection of data on several potential risk factors and confounders as well as detailed subtype information.
In summary, percent MD partially mediated the associations between prior breast biopsy and breast cancer risk in both pre-and postmenopausal women as well as mediated the associations with nulliparity, age at first birth, and HT use among postmenopausal women. Percent MD did not mediate the associations with breast cancer risk for some factors, such as family history of breast cancer. Results were generally similar for all invasive, ER+, PR+, and HER2− breast cancer. This study suggests that some breast cancer risk factors at least partially influence breast cancer risk through alterations in breast tissue composition, changes which are particularly evident after menopause.
